Home > Insider Trading > Filing (0001415889-24-027711)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1660334	Verrica Pharmaceuticals Inc.	VRCA	Pharmaceutical Preparations (2834)	463137900

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
2043558	Jayson Rieger	C/O Verrica Pharmaceuticals Inc. 44 W. Gay St., Suite 400 West Chester PA 19380	Ceo And President	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-11-22	280,898	$0.00	832,826	No	4	P	Direct
Common Stock	Acquisiton	2024-11-26	50,000	$0.00	882,826	No	4	G	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct
No	4	G	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Warrants (right to buy)	Acquisiton	2024-11-22	140,449	$0.00	140,449	$1.07
Common Stock	Series B Warrants (right to buy)	Acquisiton	2024-11-22	140,449	$0.00	140,449	$1.34

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
140,449	2024-11-22	2025-11-22	No	4	P	Direct
140,449	2024-11-22	2029-11-22	No	4	P	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	150	Indirect	By child
Common Stock	2,302	Indirect	By trust
Common Stock	2,301	Indirect	By trust
Common Stock	2,302	Indirect	By trust

Footnotes

The reported securities are included within 280,898 investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.
These shares are held in separate trusts for the benefit of the Reporting Person's immediate family members. The Reporting Person is a co-trustee of each trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.